Jazz Pharmaceuticals and Zymeworks Inc. entered into a $50M licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2. Aside from the $50M upfront payment, Jazz is putting $325M more on the line if it decides to continue the collaboration.
Jazz Drops $50M for Exclusive Rights to Zymeworks’ Bispecific HER2 Hopeful
Share: